SonoClear successfully closes a funding round
Our portfolio company SonoClear has closed an oversubscribed funding round of over 45 million NOK. In addition to existing investors and owners, much of SonoClear's funding came from Norwegian family-owned investment companies. The funding will take SonoClear all the way to FDA approval. Most of the funding will go to the final phase of product testing and clinical evaluation, which will take place in Germany.
SonoClear stems from the ultrasound and image-guided therapy environment in Trondheim, Norway. SonoClear is developing an advanced acoustic coupling fluid to improve diagnostic accuracy in ultrasound-guided procedures, particularly in neurosurgery. Precise removal of tumor is key to positive outcomes for patients and tumor visualization using the SonoClear System enables the neurosurgeons to achieve thatwithout the use of intraoperative MRI.
SonoClear System has been clinically tested and is awaiting a few final tests before submission for FDA approval.
Read more here.
Read about SonoClear here.